hematologic malignancies
The company is gearing up to launch a new rapid NGS test for acute myeloid leukemia and a liquid biopsy comprehensive genomic profiling assay.
Bionano Genomics Upbeat on Further Clinical Adoption of Optical Genome Mapping With New CPT Code
Premium
The Category I CPT code paves the way for reimbursement of OGM-based clinical tests, though details on pricing and insurance coverage are still unclear.
Written by early OGM adopters, the framework describes best practices for the technology's clinical implementation for hematological malignancies.
Agilent Licenses Roswell Park-Developed Blood Cancer Test
The assay is intended to aid oncologists in diagnosing and directing appropriate treatment for patients with a variety of hematologic cancers.
Invivoscribe, Complete Genomics Partner to Develop, Commercialize Oncology Biomarker Tests
The companies will collaborate to develop biomarkers tests for minimal residual disease (MRDs) in research and clinical setting using the DNBSeq sequencer.